The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells

Auclair C (1987) Multimodal action of antitumor agents on DNA: The ellipticine series. Arch Biochem Biophys 259: 1-14.10.1016/0003-9861(87)90463-2Search in Google Scholar

Bedrníček J, Vícha A, Jarošová M, Holzerová M, Činátl J Jr, Michaelis M, Činátl J, Eckschlager T (2005) Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. Neoplasma 52: 415-419.Search in Google Scholar

Borek-Dohalská L, Frei E, Stiborová M (2004) DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69: 603-615.10.1135/cccc20040603Search in Google Scholar

Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216.10.1038/nrc1014Search in Google Scholar

Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64: 289-295.10.1016/S0006-2952(02)01072-9Search in Google Scholar

Hardesty CT, Chaney NA, Mead JA (1972) The effect of route of administration on the distribution of ellipticine in mice. Cancer Res 32: 1884-1889.Search in Google Scholar

Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernáiz Driever P, Klingebiel T, Cinatl J Jr (2003) Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104: 36-43.10.1002/ijc.10917Search in Google Scholar

Lesca P, Beaune P, Monsarrat B (1981) Ellipticines and human liver microsomes: spectral interaction with cytochrome P-450 and hydroxylation. Inhibition of arylhydrocarbon metabolism and mutagenicity. Chem-Biol Interact 36: 299-309.Search in Google Scholar

Maris JM, Mathay KK (1999) Molecular biology of neuroblastomas. J Clin Oncol 17: 2264-2279.Search in Google Scholar

Murray GI, Weaver RJ, Paterson PJ, Ewen SW, Melvin WT, Burke MD (1993) Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol 169: 347-353.10.1002/path.1711690312Search in Google Scholar

Stiborová M, Bieler CA, Wiessler M, Frei E (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62: 1675-1684.10.1016/S0006-2952(01)00806-1Search in Google Scholar

Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E (2003a) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16: 38-47.10.1021/tx020081812693029Search in Google Scholar

Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E (2003b) DNA adduct formation by the anticancer drug ellipticine in rats determined by ³²P-postlabeling. Int J Cancer 107: 885-890.10.1002/ijc.1151114601046Search in Google Scholar